Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Non Small Cell Lung Carcinoma NSCLC 2NSCLC 2Melanoma 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × CP protocol × Clear all
NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

AstraZeneca

Phase 3 Active not recruiting
328 enrolled 23 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡